Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by its aggressive progression and dismal prognosis. Advances in epigenetic profiling, specifically DNA methylation analysis, have significantly deepened our understanding of PDAC pathogenesis. This rev...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Epigenomes |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4655/8/4/41 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850049791925420032 |
|---|---|
| author | Peiyi Liu Juliette Jacques Chang-Il Hwang |
| author_facet | Peiyi Liu Juliette Jacques Chang-Il Hwang |
| author_sort | Peiyi Liu |
| collection | DOAJ |
| description | Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by its aggressive progression and dismal prognosis. Advances in epigenetic profiling, specifically DNA methylation analysis, have significantly deepened our understanding of PDAC pathogenesis. This review synthesizes findings from recent genome-wide DNA methylation studies, which have delineated a complex DNA methylation landscape differentiating between normal and cancerous pancreatic tissues, as well as across various stages and molecular subtypes of PDAC. These studies identified specific differentially methylated regions (DMRs) that not only enhance our grasp of the epigenetic drivers of PDAC but also offer potential biomarkers for early diagnosis and prognosis, enabling the customization of therapeutic approaches. The review further explores how DNA methylation profiling could facilitate the development of subtype-tailored therapies, potentially improving treatment outcomes based on precise molecular characterizations. Overall, leveraging DNA methylation alterations as functional biomarkers holds promise for advancing our understanding of disease progression and refining PDAC management strategies, which could lead to improved patient outcomes and a deeper comprehension of the disease’s underlying biological mechanisms. |
| format | Article |
| id | doaj-art-e7ecf548562a4588912ff0d5bcfab0c0 |
| institution | DOAJ |
| issn | 2075-4655 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Epigenomes |
| spelling | doaj-art-e7ecf548562a4588912ff0d5bcfab0c02025-08-20T02:53:38ZengMDPI AGEpigenomes2075-46552024-11-01844110.3390/epigenomes8040041Epigenetic Landscape of DNA Methylation in Pancreatic Ductal AdenocarcinomaPeiyi Liu0Juliette Jacques1Chang-Il Hwang2Department of Microbiology and Molecular Genetics, College of Biological Sciences, University of California, Davis, Davis, CA 95616, USADepartment of Microbiology and Molecular Genetics, College of Biological Sciences, University of California, Davis, Davis, CA 95616, USADepartment of Microbiology and Molecular Genetics, College of Biological Sciences, University of California, Davis, Davis, CA 95616, USAPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by its aggressive progression and dismal prognosis. Advances in epigenetic profiling, specifically DNA methylation analysis, have significantly deepened our understanding of PDAC pathogenesis. This review synthesizes findings from recent genome-wide DNA methylation studies, which have delineated a complex DNA methylation landscape differentiating between normal and cancerous pancreatic tissues, as well as across various stages and molecular subtypes of PDAC. These studies identified specific differentially methylated regions (DMRs) that not only enhance our grasp of the epigenetic drivers of PDAC but also offer potential biomarkers for early diagnosis and prognosis, enabling the customization of therapeutic approaches. The review further explores how DNA methylation profiling could facilitate the development of subtype-tailored therapies, potentially improving treatment outcomes based on precise molecular characterizations. Overall, leveraging DNA methylation alterations as functional biomarkers holds promise for advancing our understanding of disease progression and refining PDAC management strategies, which could lead to improved patient outcomes and a deeper comprehension of the disease’s underlying biological mechanisms.https://www.mdpi.com/2075-4655/8/4/41DNA methylationpancreatic ductal adenocarcinomapancreatic cancerwhole-genome bisulfite sequencingmetastasis |
| spellingShingle | Peiyi Liu Juliette Jacques Chang-Il Hwang Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma Epigenomes DNA methylation pancreatic ductal adenocarcinoma pancreatic cancer whole-genome bisulfite sequencing metastasis |
| title | Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma |
| title_full | Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma |
| title_fullStr | Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma |
| title_full_unstemmed | Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma |
| title_short | Epigenetic Landscape of DNA Methylation in Pancreatic Ductal Adenocarcinoma |
| title_sort | epigenetic landscape of dna methylation in pancreatic ductal adenocarcinoma |
| topic | DNA methylation pancreatic ductal adenocarcinoma pancreatic cancer whole-genome bisulfite sequencing metastasis |
| url | https://www.mdpi.com/2075-4655/8/4/41 |
| work_keys_str_mv | AT peiyiliu epigeneticlandscapeofdnamethylationinpancreaticductaladenocarcinoma AT juliettejacques epigeneticlandscapeofdnamethylationinpancreaticductaladenocarcinoma AT changilhwang epigeneticlandscapeofdnamethylationinpancreaticductaladenocarcinoma |